Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct‐acting anti‐virals

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|44|8|866-876

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.44, Iss.8, 2016-10, pp. : 866-876

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost‐Effectiveness of New Direct‐Acting Antivirals to Prevent Post–Liver Transplant Recurrent Hepatitis

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 15, Iss. 7, 2015-07 ,pp. : 1817-1826

John Wiley & Sons Inc

Access to resources Recommend Favorite

Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals

By  

Oncology, Vol. 91, Iss. 6, 2016-10 ,pp. : 341-347

Karger

Access to resources Recommend Favorite

Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 516-525

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of hepatitis C: the use of the new pangenotypic direct‐acting antivirals in “special populations”

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 28-33

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct‐acting antivirals has failed

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 129-134

John Wiley & Sons Inc

Access to resources Recommend Favorite